ACADIA Pharmaceuticals Inc. (ACAD): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

ACADIA Pharmaceuticals ( ACAD) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.2%. By the end of trading, ACADIA Pharmaceuticals fell $0.41 (-2.1%) to $18.63 on light volume. Throughout the day, 1,124,880 shares of ACADIA Pharmaceuticals exchanged hands as compared to its average daily volume of 3,426,700 shares. The stock ranged in price between $18.50-$19.06 after having opened the day at $18.94 as compared to the previous trading day's close of $19.04. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 37.2%, IntelliPharmaCeutics International ( IPCI), down 20.4%, Pernix Therapeutics Holdings ( PTX), down 16.9% and Abaxis ( ABAX), down 16.1%.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. ACADIA Pharmaceuticals has a market cap of $1.7 billion and is part of the health care sector. Shares are up 309.5% year to date as of the close of trading on Thursday. Currently there are 8 analysts that rate ACADIA Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates ACADIA Pharmaceuticals as a sell. Among the areas we feel are negative, one of the most important has been weak operating cash flow.

On the positive front, Senesco Technologies ( SNTI), up 56.1%, Gentium SpA ( GENT), up 49.7%, GW Pharmaceuticals PLC ADR ( GWPH), up 24.7% and Idera Pharmaceuticals ( IDRA), up 16.3% , were all gainers within the drugs industry with Novo Nordisk A/S ( NVO) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%